CG Oncology, Inc.
Congressional Trades
No congressional trades in CGON on record.
Whale Activity
- Increased84
- New37
- Held32
- Decreased70
- Closed30
- No prior filing10
| Filer | Shares | Value | Change |
|---|---|---|---|
| RTW INVESTMENTS, LP | 8.5M | $603.6M | held |
| T. Rowe Price Investment Management, Inc. | 6.7M | $476.9M | increased |
| Decheng Capital LLC | 6.4M | $451.7M | held |
| BlackRock, Inc. | 6.3M | $450.0M | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 4.9M | $348.6M | decreased |
| FMR LLC | 4.6M | $325.7M | increased |
| TCG Crossover Management, LLC | 3.7M | $260.2M | held |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6M | $253.4M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5M | $249.2M | increased |
| STATE STREET CORP | 3.2M | $229.3M | decreased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.1M | $220.2M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2M | $157.8M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Kuan ArthurChief Executive Officer · Director | Purchase | +30.0K | $78.88 | $2.4M | Nov 18, 2026 | Form 4 ↗ |
| Kalofonos IsabelChief Commercial Officer | Purchase | +3,751 | $79.75 | $299K | Nov 18, 2026 | Form 4 ↗ |
| POST LEONARD EDirector · Director | Sale | −1,000 | $92.00 | $92K | Nov 16, 2026 | Form 4 ↗ |
| POST LEONARD EDirector · Director | Sale | −500 | $62.48 | $31K | Oct 15, 2026 | Form 4 ↗ |
| POST LEONARD EDirector · Director | Sale | −500 | $61.65 | $31K | Oct 15, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Sale | −1,000 | $72.98 | $73K | Sep 15, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Option exercise | +1,000 | $0.60 | $600 | Sep 15, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Sale | −1,000 | $74.54 | $75K | Aug 14, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Option exercise | +1,000 | $0.60 | $600 | Aug 14, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Sale | −1,000 | $71.17 | $71K | Jul 15, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Option exercise | +1,000 | $0.60 | $600 | Jul 15, 2026 | Form 4 ↗ |
| Mulay JamesDirector | Sale | −24.2K | $75.16 | $1.8M | Jul 10, 2026 | Form 4 ↗ |
| Mulay JamesDirector | Option exercise | +24.2K | $26.63 | $644K | Jul 10, 2026 | Form 4 ↗ |
| Liu Brian Guan-ChyunDirector | Purchase | +371.1K | $66.87 | $24.8M | Jun 25, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Sale | −5,000 | $70.00 | $350K | Jun 24, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Option exercise | +5,000 | $0.60 | $3K | Jun 24, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Sale | −5,000 | $65.00 | $325K | Jun 22, 2026 | Form 4 ↗ |
| POST LEONARD EDirector | Option exercise | +5,000 | $0.60 | $3K | Jun 22, 2026 | Form 4 ↗ |
| Mulay JamesDirector | Sale | −1,310 | $60.12 | $79K | Jun 15, 2026 | Form 4 ↗ |
| Mulay JamesDirector | Option exercise | +1,310 | $12.59 | $16K | Jun 15, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 2.9M | $203.6M | 0.53% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, INC. | 2.6M | $182.9M | 0.26% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.4M | $169.3M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.9M | $134.6M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.8M | $128.8M | 1.20% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.7M | $122.2M | 0.06% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.1M | $79.2M | 0.54% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 860.0K | $61.1M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 806.8K | $57.4M | 0.17% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund Fidelity Securities Fund | 797.4K | $56.8M | 0.65% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list CGON's shares (CUSIP 156944100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Roderick WongSCHEDULE 13G/A · passive (13G) · 8.5M shares9.7%
Aug 14, 2026 · ↗ - RTW Investments, LPSCHEDULE 13G/A · passive (13G) · 8.5M shares9.7%
Aug 14, 2026 · ↗ - James B. TananbaumSCHEDULE 13G/A · passive (13G) · 4.3M shares4.9%
Aug 14, 2026 · ↗ - Foresite Capital Management VI LLCSCHEDULE 13G/A · passive (13G) · 2.4M shares2.7%
Aug 14, 2026 · ↗ - Foresite Capital Fund VI LPSCHEDULE 13G/A · passive (13G) · 2.4M shares2.7%
Aug 14, 2026 · ↗ - Foresite Capital Opportunity Management V, LLCSCHEDULE 13G/A · passive (13G) · 857.5K shares1.0%
Aug 14, 2026 · ↗ - Foresite Capital Opportunity Fund V, L.P.SCHEDULE 13G/A · passive (13G) · 857.5K shares1.0%
Aug 14, 2026 · ↗ - Foresite Capital Management V, LLCSCHEDULE 13G/A · passive (13G) · 1.1M shares1.2%
Aug 14, 2026 · ↗ - Foresite Capital Fund V, L.P.SCHEDULE 13G/A · passive (13G) · 1.1M shares1.2%
Aug 14, 2026 · ↗ - Wellington Management Company LLPSCHEDULE 13G/A · passive (13G) · 5.3M shares5.7%
Aug 13, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming CG Oncology, Inc. as the client.
Government Contracts
No federal contract awards found for CG Oncology, Inc..
U.S. Patents
No USPTO patent applications found for CG Oncology, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating income | -$190.8M | -$114.7M | -$55.4M |
| Net income | -$161.0M | -$88.0M | -$48.6M |
| Diluted EPS | -$2.08 | -$1.41 | -$15.65 |
| Operating cash flow | -$132.3M | -$78.7M | -$45.7M |
| Cash and equivalents | $32.5M | $257.1M | $8.3M |
| Total assets | $791.6M | $754.8M | $199.3M |
| Total liabilities | $39.0M | $21.4M | $14.5M |
| Shareholders' equity | $752.6M | $733.4M | -$123.1M |
As CG Oncology, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗
Stock Splits
No stock splits in CGON's price history.
Material Events (8-K)
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsNov 16, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsNov 6, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 8, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeMay 26, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 8, 2026
EDGAR ↗
